CN105327405B - Carried stent and preparation method thereof for treating cervicitis - Google Patents

Carried stent and preparation method thereof for treating cervicitis Download PDF

Info

Publication number
CN105327405B
CN105327405B CN201510707832.1A CN201510707832A CN105327405B CN 105327405 B CN105327405 B CN 105327405B CN 201510707832 A CN201510707832 A CN 201510707832A CN 105327405 B CN105327405 B CN 105327405B
Authority
CN
China
Prior art keywords
cervicitis
preparation
carried stent
liquid
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510707832.1A
Other languages
Chinese (zh)
Other versions
CN105327405A (en
Inventor
魏坤
梁猛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China University of Technology SCUT
Original Assignee
South China University of Technology SCUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China University of Technology SCUT filed Critical South China University of Technology SCUT
Priority to CN201510707832.1A priority Critical patent/CN105327405B/en
Publication of CN105327405A publication Critical patent/CN105327405A/en
Application granted granted Critical
Publication of CN105327405B publication Critical patent/CN105327405B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/146—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses the carried stent and preparation method thereof for treating cervicitis, this method adds a certain amount of NaCl and Ceftriaxone Sodium, mixture is dispersed into uniform liquid by homogenizer predominantly by PLGA adding into dichloromethane.Then aforesaid liquid is slowly dropped in PVA solution, by stirring to get microballoon that is porous and being loaded with Ceftriaxone Sodium, is lyophilized after being rinsed with deionized water to get dry drug bearing microsphere is arrived.Microballoon is placed in cylindrical mold, is put in 70 DEG C of baking oven and keeps the temperature 3 hours, obtain final carried stent.Because the catabolite of PLGA is lactic acid and acetic acid, side effect not will cause to body, and directly act on inflammation part along with the release of drug, have important meaning for the treatment of cervicitis while scaffold degradation.

Description

Carried stent and preparation method thereof for treating cervicitis
Technical field
The present invention relates to the preparation methods of cervicitis repair medicine material, and in particular to the load medicine for treating cervicitis Bracket and preparation method thereof.
Background technique
Cervicitis is a kind of common gynecological disease because canal of uterine cervix mucous epithelium is simple columnar epithelium, easily by Infection, the general utilization ratio of drug of drug therapy especially oral drugs is lower, and drug is not easy to reach this position, in addition being related to hidden It the problems such as private, will not generally be cured in time, slowly develop into chronic cervicitis disease.
PLGA is the polymer of lactic acid and hydroxyacetic acid, and the final product of hydrolysis is water and carbon dioxide, intermediate product cream Acid is also internal normal sugar metabolism product, so the polymer is nontoxic, nonirritant, has good biocompatibility.It is based on The above-mentioned property of PLGA, therefore PLGA is widely used in the preparation of microballoon, micro-capsule, nanoparticle etc..Therefore, the present invention provides for controlling Treat the carried stent of cervicitis.
Summary of the invention
It is an object of the invention to overcome deficiencies of the prior art, the load medicine branch for treating cervicitis is provided Frame and preparation method thereof.
For treating the preparation method of the carried stent of cervicitis comprising the following steps:
(1) PLGA of 0.5~0.8g is dissolved in 5~6ml methylene chloride；
(2) 0.1~0.15gNaCl and the mixing of 0.1~0.15g Ceftriaxone Sodium are weighed, the liquid that step (1) obtains is added to In body, by homogenizer, 4~5min is stirred with the revolving speed of 4500~5000rpm, so that substance is evenly dispersed in a liquid；
(3) PVA for weighing 2~2.5g is dissolved in 200~220ml deionized water；
(4) step (2) finally obtained mixing liquid is added in the liquid that step (3) obtains, and with 250~ The revolving speed of 350rpm stirs, and stirs 6~8h；
(5) after stirring, thus obtained microsphere is cleaned with deionized water, is then lyophilized；
(6) after being lyophilized, dry microballoon is encased in columnar mould, in 65~70 DEG C of baking oven 2~3h of inside holding, heat preservation After, obtain the carried stent.
Further implement ground, step (5) wash number for clean thus obtained microsphere with deionized water is 5~8 times.
Further implement ground, the time of step (5) described freeze-drying is 24~36h.
The present invention also provides the carried stents for being used to treat cervicitis as made from the preparation method.Because of the drop of PLGA Solving product is lactic acid and acetic acid, not will cause side effect to body, and along with the release of drug while scaffold degradation, directly Inflammation part is acted on, has important meaning for the treatment of cervicitis.
Compared with prior art, present invention has an advantage that
1) PLGA catabolite does not have any side effect, good biocompatibility to bodily tissue；
2) porous microsphere increases porosity, is more advantageous to the release of drug；
3) inflammation part is directly acted on, the utilization rate of drug is improved；
4) lasting drug release, pharmaceutical release time is long, is better than oral medication.
Detailed description of the invention
Fig. 1 is the porosity comparison diagram of different temperatures lower bracket；
Fig. 2 is the drug release patterns of different support；
Specific embodiment
Below with reference to embodiment, explanation is further explained to embodiments of the present invention, but specific embodiment is not right The present invention does any restriction.
Embodiment 1
1) PLGA of 0.5g is dissolved in 5ml methylene chloride；
2) mixing of 0.1gNaCl and 0.1g Ceftriaxone Sodium is weighed, is added in (1) liquid, by homogenizer, with The revolving speed of 5000rpm stirs 5min, so that substance is evenly dispersed in a liquid；
3) PVA for weighing 2g is dissolved in 200ml deionized water；
4) (2) mixing liquid is slowly added into (3), and with the stirring of the revolving speed of 300rpm, stirs 6h；
5) after stirring, thus obtained microsphere is cleaned 5 times with deionized water, is then lyophilized, freeze-drying time is for 24 hours；
6) after being lyophilized, dry microballoon is encased in columnar mould, in 50 DEG C of baking oven inside holding 3h, after heat preservation, Obtain carried stent.
Embodiment 2
1) PLGA of 0.5g is dissolved in 5ml methylene chloride；
2) mixing of 0.1gNaCl and 0.1g Ceftriaxone Sodium is weighed, is added in (1) liquid, by homogenizer, with The revolving speed of 5000rpm stirs 5min, so that substance is evenly dispersed in a liquid；
3) PVA for weighing 2g is dissolved in 200ml deionized water；
4) (2) mixing liquid is slowly added into (3), and with the stirring of the revolving speed of 300rpm, stirs 6h；
5) after stirring, microballoon is cleaned 5 times with deionized water, is then lyophilized, freeze-drying time is for 24 hours；
6) after being lyophilized, dry microballoon is encased in columnar mould, in 70 DEG C of baking oven inside holding 3h, after heat preservation, Obtain carried stent.
Embodiment 3
1) PLGA of 0.5g is dissolved in 5ml methylene chloride；
2) mixing of 0.1gNaCl and 0.1g Ceftriaxone Sodium is weighed, is added in (1) liquid, by homogenizer, with The revolving speed of 5000rpm stirs 5min, so that substance is evenly dispersed in a liquid；
3) PVA for weighing 2g is dissolved in 200ml deionized water；
4) (2) mixing liquid is slowly added into (3), and with the stirring of the revolving speed of 300rpm, stirs 6h；
5) after stirring, microballoon is cleaned 5 times with deionized water, is then lyophilized, freeze-drying time is for 24 hours；
6) after being lyophilized, dry microballoon is encased in columnar mould, in 90 DEG C of baking oven inside holding 3h, after heat preservation, Obtain carried stent.
Embodiment 4
Brace aperture rate comparative experiments
Every kind of bracket takes 3 Duplicate Samples, and the row's of progress alcohol method measures the porosity of bracket respectively.It is available from table 1 The average value of the porosity of bracket is 38.3771% at 50 DEG C, and the average value of the porosity of bracket is 20.9916% at 70 DEG C, The average value of the porosity of bracket is 9.7378% at 90 DEG C.From Fig. 1 it can also be seen that as the temperature rises, the hole of bracket Gap rate is gradually reduced.
1 different temperatures lower bracket porosity data of table
Embodiment 5
Drug release comparative test
From figure 2 it can be seen that 50 DEG C of brace aperture rate is very big, the contact to drug with body fluid is extremely advantageous, but not The phenomenon of burst release for exempting to have drug, causes the concentration of initial stage drug to increase rapidly, damages to body.Bracket at 70 DEG C Burst drug release phenomenon reduce, drug entirely release the stage release more uniformly.90 DEG C compared with 70 DEG C, first 15 days Distinguish unobvious, latter 15 days as can be seen that 90 DEG C of stent drug burst size is obviously reduced.Medicine is carried when to sum up can be derived that 70 DEG C Bracket is ideal.
The present invention is based on PLGA to have good biocompatibility, it is first prepared into porous microsphere, and principle is to make NaCl is added during standby, by the dissolution of NaCl so that there are holes in microballoon, then microballoon is prepared by way of heating At bracket, equally there is the presence of hole in bracket between ball and ball, further increase porosity, is conducive to the release of drug.It carries The drug entered is Ceftriaxone Sodium, which directly acts on inflammation part, improves the utilization rate of drug, and drug is certain Sustained release in time.

Claims (4)

1. the preparation method for the carried stent for treating cervicitis, characterized in that it comprises the following steps:
(1) PLGA of 0.5 ~ 0.8g is dissolved in 5 ~ 6ml methylene chloride；
(2) 0.1 ~ 0.15gNaCl and the mixing of 0.1 ~ 0.15g Ceftriaxone Sodium are weighed, is added in the liquid that step (1) obtains, By homogenizer, 4 ~ 5min is stirred with the revolving speed of 4500 ~ 5000rpm, so that substance is evenly dispersed in a liquid；
(3) PVA for weighing 2 ~ 2.5g is dissolved in 200 ~ 220ml deionized water；
(4) step (2) finally obtained mixing liquid is added in the liquid that step (3) obtains, and with 250 ~ 350rpm's Revolving speed stirring, stirs 6 ~ 8h；
(5) after stirring, thus obtained microsphere is cleaned with deionized water, is then lyophilized；
(6) after being lyophilized, dry microballoon is encased in columnar mould, in 70 DEG C of baking oven 2 ~ 3h of inside holding, after heat preservation, is obtained To the carried stent.
2. according to claim 1 for treating the preparation method of the carried stent of cervicitis, which is characterized in that step (5) wash number for cleaning thus obtained microsphere with deionized water is 5 ~ 8 times.
3. according to claim 1 for treating the preparation method of the carried stent of cervicitis, which is characterized in that step (5) time of the freeze-drying is 24 ~ 36h.
4. obtained for treating the carried stent of cervicitis by any one of claim 1 ~ 3 preparation method.
CN201510707832.1A 2015-10-23 2015-10-23 Carried stent and preparation method thereof for treating cervicitis Active CN105327405B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510707832.1A CN105327405B (en) 2015-10-23 2015-10-23 Carried stent and preparation method thereof for treating cervicitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510707832.1A CN105327405B (en) 2015-10-23 2015-10-23 Carried stent and preparation method thereof for treating cervicitis

Publications (2)

Publication Number Publication Date
CN105327405A CN105327405A (en) 2016-02-17
CN105327405B true CN105327405B (en) 2019-01-29

Family

ID=55278302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510707832.1A Active CN105327405B (en) 2015-10-23 2015-10-23 Carried stent and preparation method thereof for treating cervicitis

Country Status (1)

Country Link
CN (1) CN105327405B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420016D0 (en) * 2004-09-09 2004-10-13 Leuven K U Res & Dev Controlled release oral delivery system
WO2010062678A2 (en) * 2008-10-30 2010-06-03 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
MX356750B (en) * 2012-07-16 2018-06-12 Laccure Ab Pharmaceutical compositions containing oligomeric lactic acid.
CN103212116A (en) * 2013-04-19 2013-07-24 华南理工大学 Method for constructing three-dimensional scaffold by polymorphous low-grade adenocarcinoma (PLGA)/calcium carbonate porous composite microsphere

Also Published As

Publication number Publication date
CN105327405A (en) 2016-02-17

Similar Documents

Publication Publication Date Title
US11130824B2 (en) Method for producing hydrogels coupling high elastic modulus and absorbance
Thakur et al. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants
CN106750398B (en) Carry medicine chitosan/dual cross-linked hydrogel of sodium alginate and its preparation method and application
CN105517536B (en) The sustained-release composition of injectable and its for treatment of arthritis disease and ache related method
EP2485717B1 (en) Delivery system for sustained release of a calcium-channel blocking agent
CN108078911A (en) Thermotropic hydrogel sustained release veterinary drug injection for animal contraception and preparation method thereof
Padmasri et al. A comprehensive review on in situ gels
CN106362223A (en) Porous silk fibroin microneedle administration device and preparation method thereof
Yassin et al. Chitosan beads as a new gastroretentive system of verapamil
CN104840428B (en) A kind of hyaluronic acid-chitosan microballoon for being loaded with epidermal growth factor and its preparation method and application
Iswandana et al. Preparation of calcium alginate-tetrandrine beads using ionic gelation method as colon-targeted dosage form
US9700630B2 (en) Low molecular weight methyl cellulose-based parenteral drug delivery system
CN104740641B (en) A kind of slow control-release microsphere composition of glucose sensitive and preparation method thereof
CN105327405B (en) Carried stent and preparation method thereof for treating cervicitis
CN106667958A (en) Polypeptide sustained-release microsphere preparation and preparation method thereof
KR101898816B1 (en) Parenteral Drug Delivery System based on low Molecular Polysaccharides
Dhir et al. An Overview of In Situ gelling system.
CN106377290B (en) A kind of medicine-carried titanium nail and load medicine titanium nail and preparation method thereof
JP2017511371A (en) Exenatide-containing composition and method for producing the same
CN103690993B (en) Scaffold material capable of blood sugar induced controlled-release of drugs and used for periodontal treatment and preparation method thereof
Kohli et al. Ethylcellulose floating microspheres of antidiabetic agent: in vitro and in vivo evaluation
CN114762675A (en) Controlled release type soluble rabies vaccine microneedle
CN113197842A (en) Cannabidiol injectable hydrogel, preparation method and application thereof
Mittal et al. Hydrogel Breakthroughs in Biomedicine: Recent Advances and Implications
CN111358934A (en) Leuprolide acetate long-acting pharmaceutical preparation combination and use method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant